Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity. - Wikidata - awgldk - TriplyDB

Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity.

Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity.

http://www.wikidata.org/entity/Q33967100

about

Targeting interleukin-1 in heart disease Novel Allosteric Modulators of G Protein-coupled Receptors Evasion of inflammasome activation by microbial pathogens IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?A novel human anti-interleukin-1β neutralizing monoclonal antibody showing in vivo efficacy Interleukin-1β-Targeted Vaccine Improves Glucose Control and β-Cell Function in a Diabetic KK-Ay Mouse Model.Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes Bridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL-1β Kinetics.How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes.Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events.A systematic review of biologics for the treatment of noninfectious uveitis.Current approaches to fine mapping of antigen-antibody interactions.Selective allosteric antibodies to the insulin receptor for the treatment of hyperglycemic and hypoglycemic disorders.Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases?Pharmacological treatment options for cryopyrin-associated periodic syndromes.Effect of Gevokizumab on Interleukin-1β-Mediated Cytochrome P450 3A4 and Drug Transporter Repression in Cultured Human Hepatocytes.XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases.Inhibition of insulin receptor function by a human, allosteric monoclonal antibody: a potential new approach for the treatment of hyperinsulinemic hypoglycemia.Safety and Efficacy of Gevokizumab in Patients with Behçet's Disease Uveitis: Results of an Exploratory Phase 2 Study.Investigational drugs in systemic vasculitis.

P2860

Q27009347-5E7C01A3-6462-4FAD-87AA-C4F8D697B41D Q28081112-D47EB70D-B5C2-4A36-B953-A6A8B3C009AE Q28082757-3DC87A0F-6C5A-4860-AD5A-8E904D670EF2 Q30251741-BE043D9E-13D5-4004-94A5-BB7B8B907551 Q33573612-D3F3323B-E3B1-40C9-B554-59C54A71183D Q36010679-D8F3319E-4527-4B9A-B7F6-7BE433986C6D Q36109128-DBF78191-E0F1-4AC6-B2CE-1B2B62438BC1 Q36702456-62539372-BE70-4042-8D6F-4A0C02BA5649 Q37064752-E5718063-3863-4A43-A7F2-32DF0EBC7713 Q38008700-F90ECEDE-C46F-4B22-998A-324F409430F2 Q38068969-D59767B3-8FD3-4D3C-B864-FC33B12FF0ED Q38196449-37C275D8-77C2-4B44-A0C6-3C06B687BB59 Q38215993-187E93DD-EF8A-4228-BEB9-EFE0FD83E40F Q38235580-C2E03553-2165-4593-958F-CFB6C49F148B Q38674213-AFAC9FA4-EA5F-4D38-AB32-E15C4E18A34E Q38750643-4C1F86E3-254B-4719-9F88-F8914CFA4D48 Q39635974-4480E907-96C0-4551-A2C6-33C545664E7A Q41966485-1CDFCB26-9541-409B-8A65-E177D712BB0C Q46202919-EE153F98-F9F0-4195-91BC-E44D4BC14EB0 Q51834131-140880D6-8113-4A7E-9CF1-1AD5D9770741

P2860

Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity.

http://www.wikidata.org/entity/Q33967100

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Kinetic approach to pathway at ...... es interleukin-1beta activity.

@ast

Kinetic approach to pathway at ...... es interleukin-1beta activity.

@en

type

label

Kinetic approach to pathway at ...... es interleukin-1beta activity.

@ast

Kinetic approach to pathway at ...... es interleukin-1beta activity.

@en

prefLabel

Kinetic approach to pathway at ...... es interleukin-1beta activity.

@ast

Kinetic approach to pathway at ...... es interleukin-1beta activity.

@en

P1433

Q33967100-7B91BC84-7A1F-4B3D-A9BF-DB8EDC305BB3

P1476

Q33967100-17623B45-14D2-475B-A000-604780699934

P2093

Q33967100-12EFE8D0-5CE4-4CB2-8EED-D244A9F47D0A

Q33967100-15922272-A098-45EA-980D-34C3F8C8318A

Q33967100-24B54C89-3D42-456D-B801-16043611E08D

Q33967100-27A78033-ABAD-4E13-916B-2B9A147C8EDD

Q33967100-29DCA51F-3611-43DE-B7AC-7958A3EBA384

Q33967100-2B9B339D-5445-4FCE-BEF5-2D7ACCF38B47

Q33967100-43EEBBA1-2DA3-4FC5-957C-7D01F4790E6B

Q33967100-4DBA0AA6-6B90-4B9F-97A3-91E5AF2D2F83

Q33967100-5F199BD3-8238-4710-B74C-2F679E11B34C

Q33967100-6AE34887-1AB6-4DC3-9410-FAFF200F2AEB

P2860

Q33967100-0A17D34D-7A8B-4109-98B6-9B9C1A895FC7

Q33967100-0F18AAE0-C58E-497C-B5AA-0418EF2E6808

Q33967100-0F3D6ECD-8B5A-4697-8874-E2BEE4507639

Q33967100-1C75AEF5-6B89-40C7-8C83-1729C0D5DE0D

Q33967100-1FF6FEFF-C6A4-4858-BCE6-9FF0199949FF

Q33967100-2D0B242E-190D-44A5-926C-57539F22A258

Q33967100-2ECD2A86-E369-4CA7-839A-CD07F8B0ABA1

Q33967100-42481603-9629-4888-8D24-18FEB1128014

Q33967100-44CBEF8F-C0E5-4A3A-9C72-D47EB0869A2F

Q33967100-6654CB0A-1421-4D20-BBF8-7EAB23C360B0

P304

Q33967100-E8CC9C39-2663-4B97-B850-11536C37BA8D

P31

Q33967100-A56D8E0A-4D6A-4E4A-A3CF-9613A43B64F8

P356

Q33967100-7FBECF53-BA32-4A17-924B-B448E7DC6C73

P407

Q33967100-C05F2886-6E3F-428E-90C5-1381BEA703FB

P433

Q33967100-69BF29AC-6862-4D1C-859D-F3168E82877E

P478

Q33967100-9ACFA550-94E1-4A51-B14A-9178AE3D719B

P50

Q33967100-8C7F0E80-6B49-4E20-9E7C-68D8C8335AF5

P577

Q33967100-42A568C5-802F-4B06-B3B9-21986351CC46

P698

Q33967100-9A5D1885-BEA3-4645-AB30-909F3055E364

P932

Q33967100-16A7DD3A-8430-4F58-95D8-544E2F43BA29

P356

JBC.M110.115790

P1433

Journal of Biological Chemistry

P1476

Kinetic approach to pathway at ...... tes interleukin-1beta activity

@en

P2093

Alexander M Owyang

http://www.w3.org/2001/XMLSchema#string

Amer M Mirza

http://www.w3.org/2001/XMLSchema#string

Arnold H Horwitz

http://www.w3.org/2001/XMLSchema#string

David J Bohmann

http://www.w3.org/2001/XMLSchema#string

Genevieve H Nonet

http://www.w3.org/2001/XMLSchema#string

Hassan Issafras

http://www.w3.org/2001/XMLSchema#string

John A Corbin

http://www.w3.org/2001/XMLSchema#string

John J Hunter

http://www.w3.org/2001/XMLSchema#string

Kristen S Michelson

http://www.w3.org/2001/XMLSchema#string

Lisa M Gross

http://www.w3.org/2001/XMLSchema#string

P2860

A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist

The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action

The interleukin-1 family: 10 years of discovery

Interleukin-1 receptor antagonist: role in biology

The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans

T-cell interleukin 1 receptor cDNA expressed in Chinese hamster ovary cells regulates functional responses to interleukin 1.

Interleukin-1 receptor signaling rather than that of tumor necrosis factor is critical in protecting the host from the severe consequences of a polymicrobe anaerobic infection.

Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets.

P304

20607-20614

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M110.115790

http://www.w3.org/2001/XMLSchema#string

P407

P433

27

http://www.w3.org/2001/XMLSchema#string

P478

285

http://www.w3.org/2001/XMLSchema#string

P50

Daniel H Bedinger

P577

2010-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20410301

http://www.w3.org/2001/XMLSchema#string

P932

2898365

http://www.w3.org/2001/XMLSchema#string